Literature DB >> 17879946

Molecular pathogenesis and therapeutic targets in epithelial ovarian cancer.

Jeremy R Chien1, Giovanni Aletti, Debra A Bell, Gary L Keeney, Viji Shridhar, Lynn C Hartmann.   

Abstract

Ovarian cancer, the most aggressive gynecologic cancer, is the foremost cause of death from gynecologic malignancies in the developed world. Two primary reasons explain its aggressive behavior: most patients present with advanced disease at diagnosis, and die of recurrences from disease that has become resistant to conventional chemotherapies. In this paper on epithelial ovarian cancer (EOC), we will review molecular alterations associated with the few precursor lesions identified to date, followed by the more commonly recognized processes of de novo carcinogenesis, metastasis, and the development of chemoresistance. We will propose a unifying model of ovarian epithelial tumorigenesis that takes into account various hypotheses. We will also review novel approaches to overcome the major problem of chemoresistance in ovarian cancer. Finally, we will discuss advances and new challenges in the development of mouse model systems to investigate EOC precursor lesions, progression, metastasis, and chemoresistance. (c) 2007 Wiley-Liss, Inc.

Entities:  

Mesh:

Year:  2007        PMID: 17879946     DOI: 10.1002/jcb.21552

Source DB:  PubMed          Journal:  J Cell Biochem        ISSN: 0730-2312            Impact factor:   4.429


  23 in total

1.  Estrogen and progesterone receptor status and outcome in epithelial ovarian cancers and low malignant potential tumors.

Authors:  Hugo Arias-Pulido; Harriet O Smith; Nancy E Joste; Therese Bocklage; Clifford R Qualls; Allison Chavez; Eric R Prossnitz; Claire F Verschraegen
Journal:  Gynecol Oncol       Date:  2009-06-27       Impact factor: 5.482

2.  MicroRNA-19b promotes the migration and invasion of ovarian cancer cells by inhibiting the PTEN/AKT signaling pathway.

Authors:  Dan-Tong Liu; Hai-Rong Yao; Yan-Ying Li; Yang-Yang Song; Meng-Ya Su
Journal:  Oncol Lett       Date:  2018-05-10       Impact factor: 2.967

3.  HtrA1 sensitizes ovarian cancer cells to cisplatin-induced cytotoxicity by targeting XIAP for degradation.

Authors:  Xiaoping He; Ashwani Khurana; Jacie L Maguire; Jeremy Chien; Viji Shridhar
Journal:  Int J Cancer       Date:  2011-04-25       Impact factor: 7.396

4.  The detection, treatment, and biology of epithelial ovarian cancer.

Authors:  Jennifer Aa Gubbels; Nick Claussen; Arvinder K Kapur; Joseph P Connor; Manish S Patankar
Journal:  J Ovarian Res       Date:  2010-03-29       Impact factor: 4.234

5.  Adenosine induces cell cycle arrest and apoptosis via cyclinD1/Cdk4 and Bcl-2/Bax pathways in human ovarian cancer cell line OVCAR-3.

Authors:  Saeid Shirali; Mahmoud Aghaei; Mahdi Shabani; Mojtaba Fathi; Majid Sohrabi; Marzieh Moeinifard
Journal:  Tumour Biol       Date:  2013-01-24

6.  Metformin and epithelial ovarian cancer therapeutics.

Authors:  Seema Patel; Lalit Kumar; Neeta Singh
Journal:  Cell Oncol (Dordr)       Date:  2015-08-13       Impact factor: 6.730

7.  Adenovirus type 12 E1B 55-kilodalton oncoprotein promotes p53-mediated apoptotic response of ovarian cancer to cisplatin.

Authors:  Junnai Wang; Qinglei Gao; Qiang Li
Journal:  Tumour Biol       Date:  2015-03-29

8.  Extended weekly dose-dense paclitaxel/carboplatin is feasible and active in heavily pre-treated platinum-resistant recurrent ovarian cancer.

Authors:  R Sharma; J Graham; H Mitchell; A Brooks; S Blagden; H Gabra
Journal:  Br J Cancer       Date:  2009-02-17       Impact factor: 7.640

9.  Targeting insulin and insulin-like growth factor pathways in epithelial ovarian cancer.

Authors:  Marie-Claude Beauchamp; Amber Yasmeen; Ariane Knafo; Walter H Gotlieb
Journal:  J Oncol       Date:  2010-01-05       Impact factor: 4.375

10.  The insulin and igf-I pathway in endocrine glands carcinogenesis.

Authors:  Roberta Malaguarnera; Alaide Morcavallo; Antonino Belfiore
Journal:  J Oncol       Date:  2012-08-08       Impact factor: 4.375

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.